Comparison of immunohistochemistry and mRNA in situ hybridization in detecting thyroid transcription factor-1 expression in non-small cell lung carcinomas tissue

Jiang, Huiyong; Bai, Xiaoyan; Meng, Fanjun; Zhang, Xuefeng

doi:10.3892/ol.2015.3757

Cited by 6 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This contradicts the clinical histopathology finding that 70-80% of lung adenocarcinoma are positive for TTF1, while lung squamous cells are negative for TTF1 and 100% positive for TP63 (43,44). While these discrepancies might be attributed to differences between the output of RNAseq and immunohistochemistry (IHC) assays, others have reported no significant difference between TTF1 mRNA and IHC protein expression (45). These contradictions highlight the importance of ascertaining whether cell lines of interest in fact retain certain key aspects of tumor biology, prior to their use in specific studies.…”

Section: Limitations Of Cell Line Modelsmentioning

confidence: 88%

Patient-derived cell line, xenograft and organoid models in lung cancer therapy

Huo

D’Arcangelo

Tsao

2020

Transl Lung Cancer Res

View full text Add to dashboard Cite

Lung cancer accounts for most cancer-related deaths worldwide and has an overall 5-year survival rate of ~15%. Cell lines have played important roles in the study of cancer biology and potential therapeutic targets, as well as pre-clinical testing of novel drugs. However, most experimental therapies that have cleared preclinical testing using established cell lines have failed phase III clinical trials. This suggests that such models may not adequately recapitulate patient tumor biology and clinical outcome predictions.Here, we discuss and compare different pre-clinical lung cancer models, including established cell lines, patient-derived cell lines, xenografts and organoids, summarize the methodology for generating these models, and review their relative advantages and limitations in different oncologic research applications. We further discuss additional gaps in patient-derived pre-clinical models to better recapitulate tumor biology and improve their clinical predictive power.

show abstract

Section: Limitations Of Cell Line Modelsmentioning

confidence: 88%

Patient-derived cell line, xenograft and organoid models in lung cancer therapy

Huo

D’Arcangelo

Tsao

2020

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

“…We believe that the research on bitter taste receptors should be continued, due to the possibility of their potential use both in the treatment and qualification of patients who require more careful monitoring. Another limitation is the evaluation of expression at the mRNA level, which may not fully reflect the actual protein expression, although more and more studies confirm comparable results for both approaches or indicate the advantage of the approach using more standardized techniques [56][57][58].…”

Section: Discussionmentioning

confidence: 99%

TAS2R38 Bitter Taste Receptor Expression in Chronic Rhinosinusitis with Nasal Polyps: New Data on Polypoid Tissue

Jeruzal-Świątecka

Borkowska

Łaszczych

et al. 2022

IJMS

View full text Add to dashboard Cite

Studies have shown differences in TAS2R38 receptor expression in patients with chronic rhinosinusitis (CRS) compared to healthy controls. Known agonists of TAS2R38 stimulate epithelial cells, leading to robust intracellular nitric oxide (NO) production, which damages bacterial membranes, enzymes, and DNA, but also increases ciliary beat frequency. In this study we examined, using qRT-PCR, the expression of TAS2R38 receptor in nasal polyps (NP) of patients with CRS (N = 107) and in inferior turbinate mucosa (ITM) of patients with CRS and controls (N = 39), and confronted it with clinical features and the severity of the disease. The expression was shown in 43 (50.00%) samples of ITM in the study group (N = 107), in 28 (71.79%) in the control group (N = 39) (p = 0.037), and in 43 (46.24%) of NP. There were no differences in levels of the expression in all analyzed tissues. Patients who rated their symptoms at 0–3 showed higher TAS2R38 expression in ITM in comparison to the patients with 8–10 points on the VAS scale (p = 0.020). A noticeable, however not significant, correlation between the TAS2R38 expression in ITM and the Lund–Mackay CT score was shown (p = 0.068; R = −0.28). Patients with coexisting asthma had significantly higher receptor expression in the NP (p = 0.012). Our study is the first to confirm the presence of the TAS2R38 receptor in NP. Expression of the TAS2R38 receptor is reduced in the sinonasal mucosa in patients with more advanced CRS with NP.

show abstract

“…The κ statistic evaluates the level of agreement between the two methods attributable to actual agreement rather than potential agreement by chance, with a κ-coefficient of > 0.75 indicating near-perfect agreement, 0.45–0.75 indicating moderate agreement, and < 0.45 indicating slight agreement, no agreement, or a random association. 24 Test clinical sensitivity, specificity, and false-positive and false-negative rates were also calculated. 25 Results with a P value < 0.05 were considered to be statistically significant.…”

Section: Methodsmentioning

confidence: 99%

Whole‐exome sequencing improves genetic testing accuracy in pulmonary artery hypertension

et al. 2018

View full text Add to dashboard Cite

Sanger sequencing, the traditional “gold standard” for mutation detection, has been wildly used in genetic testing of pulmonary artery hypertension (PAH). However, with the advent of whole-exome sequencing (WES), few studies have compared the accuracy of WES and Sanger sequencing in routine genetic testing of PAH. PAH individuals were enrolled from Fu Wai Hospital and Shanghai Pulmonary Hospital. WES was used to analyze DNA samples from 120 PAH patients whose bone morphogenetic protein receptor type 2 (BMPR2) mutation statuses had been previously studied using Sanger sequencing. The Sanger sequencing and WES agreement was 98.3% (118/120) with near-perfect agreement (κ coefficient = 0.848). There was no significant difference between the two methods on the McNemar–Bowker test (P > 0.05). Twenty-one BMPR2 mutation carriers and 99 non-carriers were detected by Sanger sequencing. Among the 21 BMPR2 carriers detected by Sanger sequencing, one variant (c.1040 T > A) was not found by WES. Among the 99 BMPR2 non-carriers, WES detected an extra mutation carrier (c.76 + 1 G > C) missed by Sanger sequencing. Both false-positive and false-negative results were highly conserved and were re-analyzed by Sanger sequencing. WES improved the accuracy of Sanger sequencing and detected 1% (1/99) false-positive and 4.8% (1/21) false-negative results of Sanger sequencing. No false-positive and false-negative results of WES were identified in our analysis. WES is non-inferior to Sanger sequencing and may play a more important role in genetic testing of PAH patients in the future.

show abstract

Comparison of immunohistochemistry and mRNA in situ hybridization in detecting thyroid transcription factor-1 expression in non-small cell lung carcinomas tissue

Cited by 6 publications

References 19 publications

Patient-derived cell line, xenograft and organoid models in lung cancer therapy

Patient-derived cell line, xenograft and organoid models in lung cancer therapy

TAS2R38 Bitter Taste Receptor Expression in Chronic Rhinosinusitis with Nasal Polyps: New Data on Polypoid Tissue

Whole‐exome sequencing improves genetic testing accuracy in pulmonary artery hypertension

Contact Info

Product

Resources

About